StockData

Bausch Health Companies vs Zoetis

BHC and ZTS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BHC and ZTS compare

Zoetis is the larger company, worth 11 times as much as Bausch Health Companies ($34.5B against $3.2B).

Bausch Health Companies grew revenue faster over the last twelve months (10.8% versus 1.5% for Zoetis).

Zoetis keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with −7.6% at Bausch Health Companies.

Zoetis pays a dividend yielding 1.9%; Bausch Health Companies does not pay one.

Zoetis scores higher on the StockData Score (17 against 8 for Bausch Health Companies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBHCZTS
Size and price
Market cap$3.2B$34.5B
Share price$8.47$83.48
Change, 1 year34.9%−30.9%
Change, 5 years−66.5%−61.9%
Beta (5Y)0.900.06
Employees20K15K
StockData Score
Total score817 (better)
Valuation score45 (better)
Growth score22
Performance score15 (better)
Health score13 (better)
Dividend score02 (better)
Valuation
P/E–13.7×
P/S0.3× (better)3.6×
P/B–11.0×
EV/EBITDA9.3× (better)10.5×
P/FCF1.7× (better)14.9×
PEG–1.34
FCF yield58.8% (better)6.7%
Fair value$35.68$154.11
Margin of safety76.3% (better)45.8%
Growth
Revenue growth (TTM)10.8% (better)1.5%
Revenue growth, 5Y average5.0%7.2% (better)
Net income growth (TTM)−332%0.96% (better)
EPS growth (TTM)−336%5.6% (better)
EPS growth, 5Y average–12.0%
Profitability
Gross margin–71.5%
Operating margin11.2%–
Net margin−7.6%27.5% (better)
FCF margin16.8%24.3% (better)
Return on equity–64.4%
Return on invested capital5.5%–
Financial health
Debt / equity–2.87
Net debt / EBITDA7.571.85 (better)
Interest coverage0.8×–
Current ratio1.563.08 (better)
Altman Z-score0.234.07 (better)
Piotroski F-score68 (better)
Dividends and buybacks
Dividend yield–1.9%
Years of dividend growth–13
Dividend growth, 5Y average–19.0%
Buyback yield–10.6%
Shareholder yield0.00%12.5% (better)
Ownership
Held by institutions63.4%96.1%
Held by insiders31.5%0.08%
Insider net buying, 12 months−$507K (better)−$1.7M
Superinvestors holding13 (better)
Short interest, % of float2.9%4.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.